Bank of New York Mellon Corp Has $439,000 Holdings in Genocea Biosciences, Inc. (GNCA)

Bank of New York Mellon Corp raised its stake in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) by 594.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 84,119 shares of the biotechnology company’s stock after acquiring an additional 72,008 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.30% of Genocea Biosciences worth $439,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of GNCA. Northpointe Capital LLC lifted its holdings in shares of Genocea Biosciences by 9.6% during the second quarter. Northpointe Capital LLC now owns 1,336,062 shares of the biotechnology company’s stock valued at $6,974,000 after acquiring an additional 117,374 shares during the period. Schwab Charles Investment Management Inc. bought a new position in shares of Genocea Biosciences during the second quarter valued at $257,000. JPMorgan Chase & Co. bought a new position in shares of Genocea Biosciences during the first quarter valued at $217,000. Rhumbline Advisers bought a new position in shares of Genocea Biosciences during the second quarter valued at $157,000. Finally, State of Wisconsin Investment Board bought a new position in shares of Genocea Biosciences during the second quarter valued at $125,000. 57.39% of the stock is owned by institutional investors.

A number of brokerages have issued reports on GNCA. Zacks Investment Research cut Genocea Biosciences from a “hold” rating to a “sell” rating in a report on Friday, August 11th. ValuEngine lowered Genocea Biosciences from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Cowen and Company restated a “buy” rating and issued a $10.00 target price on shares of Genocea Biosciences in a research note on Tuesday, September 26th. Needham & Company LLC lowered Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $18.00 target price (up from $17.00) on shares of Genocea Biosciences in a research note on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Genocea Biosciences has a consensus rating of “Buy” and a consensus target price of $9.48.

ILLEGAL ACTIVITY NOTICE: “Bank of New York Mellon Corp Has $439,000 Holdings in Genocea Biosciences, Inc. (GNCA)” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.com-unik.info/2017/11/01/bank-of-new-york-mellon-corp-has-439000-holdings-in-genocea-biosciences-inc-gnca.html.

Shares of Genocea Biosciences, Inc. (NASDAQ GNCA) opened at 1.16 on Wednesday. The firm’s market capitalization is $33.20 million. The stock has a 50 day moving average price of $2.51 and a 200-day moving average price of $4.72. Genocea Biosciences, Inc. has a 52 week low of $1.06 and a 52 week high of $7.29.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.08). On average, equities research analysts forecast that Genocea Biosciences, Inc. will post ($1.92) earnings per share for the current year.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Institutional Ownership by Quarter for Genocea Biosciences (NASDAQ:GNCA)

What are top analysts saying about Genocea Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genocea Biosciences Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit